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The foundations of innate immunity in neurodegenerative disorderswere ﬁrst laid byDel Rio
Hortega (1919). He identiﬁed and named microglia, recognizing them as cells of mesoder-
mal origin.Van Furth in 1969 elaborated the monocyte phagocytic system with microglia as
the brain representatives. Validation of these concepts did not occur until 1987 when HLA-
DR was identiﬁed on activated microglia in a spectrum of neurological disorders. HLA-DR
had already been established as a deﬁnitivemarker of immunocompetent cells of mesoder-
mal origin. It was soon determined that the observed inﬂammatory reaction was an innate
immune response. A rapid expansion of the ﬁeld took place as other markers of an innate
immune responsewere found thatweremade by neurons, astrocytes, oligodendroglia, and
endothelial cells.Themolecules included complement proteins and their regulators, inﬂam-
matory cytokines, chemokines, acute phase reactants, prostaglandins, proteases, protease
inhibitors, coagulation factors, ﬁbrinolytic factors, anaphylatoxins, integrins, free radical
generators, and other unidentiﬁed neurotoxins.TheNimmerjahnmovies demonstrated that
resting microglia were constantly active, sampling the surround, and responding rapidly to
brain damage. Ways of reducing the neurotoxic innate immune response and stimulating
a healing response continue to be sought as a means for ameliorating the pathology in a
spectrum of chronic degenerative disorders.
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BACKGROUND
Pio Del Rio Hortega, one of the greatest of all neuroscientists,
established the basic foundation of neuroinﬂammation with his
classic 1919 paper “El tercer elemento de los centros nerviosis”
(Del Rio Hortega, 1919). He had developed an ammoniacal sil-
ver carbonate modiﬁcation of the Golgi technique. With this new
method he was able to identify small spidery cells which he named
microglia. He recognized that they were of mesodermal origin,
and that they migrated to the brain in late embryonic life. He also
recognized their phagocytic capacity by examining their reaction
to stab wounds. He categorized their morphology as resting, ame-
boid, and reactive. By further modifying his technique, he later
recognized another type of glial cell which was of epithelial origin
and had a sparse cytoplasm. He named these cells oligodendroglia,
perhaps because of the difﬁculty he encountered in staining them.
These two glial cell types made up “the third element” which
had bafﬂed Ramon y Cajal. Cajal, Hortega’s mentor and employer,
had clearly identiﬁed astrocytes with his methodology, and knew
there were still unclassiﬁed glial cells. He thought the cells identi-
ﬁed by Hortegamight be another astrocytic type that was resistant
to staining.He objected toHortega’s desire to publish his results on
oligodendroglia, and when Hortega went ahead, believing others
would make the same discovery, Cajal dismissed him. Hortega’s
own account of these travails, which he never published, were
obtained after his death, later appearing in part in Haymaker
and Adams treatise on the histopathology of the nervous system
(Haymaker and Adams, 1980a, pp. 484–485).
Hortega’s travails were not limited to his falling out with Cajal.
TheMadrid laboratory he had set up after his departure fromCajal
was bombed out in the Spanish civil war. He moved for a time to
Paris, and then to Oxford, but was uncomfortable in these loca-
tions. As a Spaniard opposed to Franco, he emigrated to Buenos
Aires in 1938 where, in 1945, he died of cancer.
His ﬁndings and their interpretation were still being actively
challenged long after his death. Some scientists supported his con-
clusions, others did not. Wilder Penﬁeld was the ﬁrst prominent
investigator to uphold Hortega. He described, in the ﬁrst issue of
theAmerican Journal of Pathology, the various stages of microglia,
going from resting to reactive (Penﬁeld, 1925). Numerous others
did differing experiments, interpreting microglia cells as being of
epithelial origin with unknown function. A detailed account of
the continuing controversy, which extended for over six decades,
appears inHaymaker andAdams (1980b,ChapterVI). This unjus-
tiﬁed controversy may help to explain why Hortega never received
a Nobel prize for his epic work.
The next giant step was taken by Ralph van Furth. He elab-
orated the concept of a monocyte phagocytic system to explain
the origin and function of resident phagocytes throughout the
body. The Memoranda endorsing the concept, which was intro-
duced at the Conference on Mononuclear Phagocytes held in
Lieden in 1969, is available on the web Chttp://www.ncbi.nlm.
nih.gov/pmc/articles/PMC2480884/pdf/bullwho00193-0157.pdf.
He and his colleagues had studied labeled monocytes and their
marrow precursors and followed their appearance as typical
macrophages in various organs, including brain (Van Furth and
Cohn, 1968). This concept replaced the vague theory of a reticulo-
endothelial system introduced byAschoff (1924) which, despite its
shortcomings, had become entrenched in medical teaching.
While van Furth’s concept of a monocyte phagocytic system
was widely accepted, its relationship to brain microglia was not.
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Fujita in particular opposed the idea that microglia were the brain
representatives of this system. He injected tritiated thymidine into
chick embryos and identiﬁed labeled brain cells which he inter-
preted as glioblasts of subependymal origin (Fujita, 1965). He did
later studies of human embryonic brain tissue and reached a sim-
ilar conclusion, that brain microglia were of epithelial and not
mesenchymal origin (Fujita, 1973; Fujita and Kitamura, 1973).
Oemichan et al. (1979) and Wood et al. (1979) also concluded
that brain microglia could not be phagocytes of monocytic origin.
The reason was that they could not detect the same surface anti-
gens on microglial cells that they were able to detect on peripheral
monocytes. The idea became established that inﬂammation of the
brain did not involve microglia, and did not occur unless there
was invasion of the brain by peripheral monocytes, which then
became transformed into macrophages.
IDENTIFICATION OF HLA-DR POSITIVE MICROGLIA IN
HUMAN BRAIN
The entry of our laboratory into the neuroinﬂammatory ﬁeld was
entirely serendipitous. Several researchers had suggested that AD
might result from a herpes infection entering through the nasal
passages because of involvement of the rhinencephalon (Ball,
1982). Our effort over some years to detect herpes virus in the
CNS had failed, although we were able to detect it in some cases
in the trigeminal nucleus, the source of herpes labialis (Walker
et al., 1989). We sought the advice of local immunologists regard-
ing what might be a broader indicator of a viral infection, and
were counseled to look for HLA-DR since this class II glycoprotein
would be responsible for presenting viral epitopes to T-cells. We
were even presented with a gift of the HB-104 cell line, known to
produce high levels of antibodies against HLA-DR.
The results astonished us. A plethora of cells was visible in
AD tissue with a morphology that was completely unfamiliar to
us. However we were able to conﬁrm that they were microglia by
showing them to the founder of our laboratory, Dr. William Gib-
son, who had been a student and biographer of Hortega (Prados
and Gibson, 1946). The morphology was identical to that pub-
lished by Del Rio Hortega (1919), permitting us to sense in a very
small way the excitement he must have experienced.
As many frustrated investigators well know, peer reviewers,
whether evaluating applications for research grants, or papers sub-
mitted to journals, are typically well versed in the dogmas of the
day. Findings that radically conﬂict with established views are too
often dismissed. Our data conﬂicted with two dogmas. The ﬁrst
was thatmicroglia were of epithelial origin andwere not immuno-
competent cells. The second was that brain inﬂammation was not
a characteristic of AD. A pathological journal rejected our initial
manuscript, reasoning that the absence of a neuropathologist as
an author explained the faulty conclusions. A peer reviewer for a
renewal of our grant dismissed it with the comment “the hypoth-
esis is ridiculous.”Nevertheless, our ﬁrst paper appeared as a brief
report in Neuroscience Letters (McGeer et al., 1987).
This ﬁnal validation of Hortega depended on the availabil-
ity of HB-104, a powerful and highly speciﬁc monoclonal anti-
body. The ﬁeld of immunohistochemistry had been opened by
Cesar Milstein’s work on the technique for producing monoclonal
antibodies. He was a co-winner of the Nobel prize in 1984 for
this accomplishment. Then, as now, the ability to visualize brain
biochemistry through the eyes of immunohistochemistry depends
on the strength and speciﬁcity of the antibodies employed. HB-
104 was a particularly good antibody, permitting us to make a
clear distinction, which had eluded other investigators, between
HLA-DR positive microglia and GFAP positive astrocytes.
We were not the ﬁrst to report class II staining of brain cells.
Lampson and Hickey (1986) had reported class II activity in
occasional cell bodies of human brain with the “morphologic
appearance of microglia or astrocytes.” Similarly deTribolet et al.
(1984) reported HLA-DR positive cells in the white matter of nor-
mal brain which they interpreted as being astrocytes (deTribolet
et al., 1984). Rogers et al. reported HLA-DR positive microglia
and astrocytes in AD in an abstract at the Society of Neuroscience
meeting in 1986 but, as in our case, formal publication was held
up by disbelief in the ﬁndings. Their work ﬁnally appeared in 1988
(Luber-Narod and Rogers, 1988; Rogers et al., 1988).
These data led to a number of unanswered questions.What was
the source of the inﬂammation in AD? Was it a special phenom-
enon or a general one that applied to many chronic neurological
disorders? If it was a general phenomenon, was it localized to the
brain or did it involve the peripheral immune system?Was it help-
ful or harmful to ongoing degenerative processes? What were the
implications for treatment? Exploration of these questions led to
the opening up of an important new ﬁeld of neuroscience, namely
neuroinﬂammation.
ESTABLISHMENT OF NEUROINFLAMMATION AS A DISTINCT
FIELD OF NEUROSCIENCE RESEARCH
The question as to whether or not the presence of activated
microglia in brain was a special one applying to AD, or a general
phenomenon was quickly answered. HLA-DR activated microglia
were observed in a variety of degenerative neurological conditions,
including Parkinson disease (PD), Pick disease, ALS, Huntington
disease, multiple sclerosis, AIDS encephalopathy, parkinsonism
dementia of Guam, and the Shy–Drager syndrome (McGeer et al.,
1988a). Their phagocytic function was easily demonstrated by
melanin being observed within the HLA-DR positive microglia
of the SN (McGeer et al., 1988b). Each of these diseases has a dif-
fering etiology, so the activated microglial response had to be the
consequence of initiating factors in each condition and not the
fundamental cause.
At this same time, the laboratory of Kreutzberg inGermanywas
carrying out work of a more fundamental nature. His team was
utilizing the facial nerve axotomymodel to examine the CNS reac-
tion to a sterile lesion outside of the CNS. They found activated
microglia enveloping damaged neurons of facial nerve cell bodies,
with phagocytosis of dead cells taking place. They concluded that
microglia might function as antigen presenting cells and thus be
the effector cells responsible for recruitment of lymphocytes to
the brain resulting in an inﬂammatory reaction. A review of their
results appeared in the ﬁrst volume of Glia (Streit et al., 1988) and
a later review (Kreutzberg, 1996).
Further groundwork was laid by four key papers which
appeared in a special issue of Glia in 1993 devoted to microglia.
They were by Ling and Wong (1993) describing the origin and
nature of microglia; Dickson et al. (1993) detailing cytokines and
microglia in Alzheimer disease and AIDS; Banati et al. (1993)
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on the cytotoxicity of microglia; and McGeer et al. (1993) on
microglia in neurodegenerative diseases generally.
Since our laboratory and that of Joe Rogers, who had founded
the Sun Health Research Institute, had identiﬁed HLA-DR acti-
vated microglia in AD, we joined forces for further investigation
of the phenomenon, particularly the role of complement. The
name complement was introduced by Paul Ehrlich in the 1890’s
to explain the heat labile factor in serum which helped antibodies
to kill microorganisms. As a result, complement was considered
to be a peripherally generated system for assisting the activity
of antibodies. It was therefore believed that complement factors
would only be found as an accompaniment to immunoglobulin
antibodies.
Eikelenboom and Stam (1982) were the ﬁrst to report the pres-
ence of complement factors inAD senile plaques. Previously it had
been reported that immunoglobulins were associated with amy-
loid deposits, which was consistent with prevailing theory (Ishii
and Haga, 1975). Our laboratory was able to detect the opsonizing
components of the classical complement pathway in association
with plaques, and the membrane attack complex in association
with dystrophic neurites, consistent with bystander lysis occurring
in AD (McGeer et al., 1989).
Working with Joseph Rogers, we were unable to detect
immunoglobulins in AD tissue using a host of antibodies. Then
Rogers explored the idea that beta amyloid protein itself might
be an activator of complement. In a classic paper he and his col-
leagues demonstrated that immunoglobulin immunostaining did
not colocalize with complement, and that beta amyloid protein
and its N-terminal fragments bound to C1q directly, thus initiat-
ing the complement cascade independently of antibodies (Rogers
et al., 1992). But what was the source of the complement proteins?
It was soon determined from RNA studies that brain itself was the
source (Johnson et al., 1992; Walker and McGeer, 1992). Mean-
while evolutionary studies were underway, establishing that the
complement system could be traced back at least as far as horse-
shoe crabs and that it was themainstay of innate immunity inmost
primitive organisms (Zhu et al., 2005). It far predated the anti-
body producing adaptive immune systemwhich is an invention of
higher vertebrates.
Two principles which had broad implications for the develop-
ing ﬁeld of neuroinﬂammation emerged from this joint endeavor.
The ﬁrst was establishing that complement was part of the innate
immune system and further that it had the potential of exacer-
bating the pathology through formation of the membrane attack
complex. The second was showing that the inﬂammatory reaction
inADdid exacerbate the pathology.Wedecided to explorewhether
patients on long term anti-inﬂammatory therapy were relatively
spared fromAD.We selected rheumatoid arthritic patients because
onset of the disease typically appears at an earlier age than AD and
involves aggressive anti-inﬂammatory therapy. The results showed
an estimated sixfold sparing of AD in rheumatoid arthritic patients
compared with age matched general populations (McGeer et al.,
1990). Many subsequent epidemiological studies, in which con-
sumption of NSAIDs in particular were targeted, conﬁrmed these
general ﬁndings (McGeer and McGeer, 1995).
Rogers was then motivated to establish a Neuroinﬂamma-
tion Working Group of 37 investigators to assemble the rapidly
accumulating data on inﬂammation in AD. The conclusion of the
group was that the data represented “a virtual textbook of inﬂam-
matory mediators.” Included were complement proteins and their
regulators, inﬂammatory cytokines, chemokines, acute phase reac-
tants, prostaglandins, proteases, protease inhibitors, coagulation
factors, ﬁbrinolytic factors, integrins, anaphylatoxins, free radical
generators, and other unidentiﬁed neurotoxins (Akiyama et al.,
2000). All are products of the innate immune system of brain,with
major contributions coming from neurons, astrocytes, microglia,
and endothelial cells.
Parkinson disease was another chronic degenerative disorder
where activated microglia were detected in association with the
SN lesions (McGeer et al., 1988b). An accidental model of PD
provided new insights into the consequences of chronic neuroin-
ﬂammation. Langston et al. (1984) had identiﬁed a group of young
drug users who suddenly developed a parkinsonian syndrome.
The causative agent (MPP+) was a metabolite of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), a contaminant in the
street drug they were using. The condition was progressive, and
autopsy studies on those who had died from this exposure years
previously showed neuroinﬂammation of the SN similar to that
observed in PD (Langston et al., 1999). We found a parallel situa-
tion in monkeys. They showed nigral degeneration and activated
microglia in the SN 5.5–15 years after systemic exposure to MPTP
(McGeer et al., 2003). These ﬁndings represent the clearest exam-
ple of how neuroinﬂammation, once initiated, can persist, and
cause continuing neurodegeneration.
Activated microglia are the pivotal cells. Their functioning
in vivo has been remarkably demonstrated by the movies of
Nimmerjahn et al. (2005). They developed mice transgenic for a
green ﬂuorescent protein in microglial cells and used two-photon
microscopy through a window in the skull to observe their behav-
ior. Microglial cells in the normal state were found not to be
dormant, as implied by their traditional designation as resting,
but were extremely active, continuously extending, and retract-
ing their processes to sense their environment. When activated
by a laser lesion of a capillary, they surrounded the lesion and
phagocytosed the leaking blood.
The innate immune system is the body’s ﬁrst line of defense.
As the Nimmerjahn movies demonstrate, it can act immediately.
As shown in chronic degenerative diseases, as well as the MPTP
model, it can maintain its activity indeﬁnitely without signiﬁ-
cant engagement of the adaptive immune system. The adaptive
immune system is slower to react but more powerful and speciﬁc
in attacking targets. It depends upon appropriate presentation of
epitopes to lymphatic organs so that lymphocytes can be cloned to
attack targets where that epitope is exposed. There is a long list of
diseases where the adaptive immune system directs self attack on
healthy tissues. These conditions are known as autoimmune dis-
orders. They differ fromAD and other chronic neurodegenerative
disorders where the adaptive immune system does not become
signiﬁcantly engaged. To distinguish between the two, we have
suggested that such diseases be described as autotoxic disorders
(McGeer and McGeer, 2000).
In theory, the self destruction in autotoxic disorders should be
milder and more amenable to therapeutic intervention than the
self destruction in autoimmune disorders. The question is how to
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ameliorate the autotoxic response? Anti-inﬂammatory and anti-
oxidant approaches have been themost widely utilized to date. But
another, and potentially more effective method may be possible.
That is to transform microglia from the attack mode, which has
been so well characterized, to a healing mode. Such a transfor-
mation might result in enhanced phagocytotic activity, coupled
with a switch from expressing inﬂammatory cytokines such as
IL-1 and TNF to expressing anti-inﬂammatory cytokines such as
IL-4 and IL-10. In the process the beneﬁcial effects of phagocytosis
might be enhanced. For example, suppressing the CD-40/CD 40L
interaction in transgenic mice enhances the phagocytic activity
of microglia and increase Aβ clearance (Tan et al., 2002). Clearly
there is much still to be learned. It can be said that, despite the
huge expansion of activity that has taken place in recent years, it
is still a ﬁeld in its infancy.
SUMMARY
Our understanding of the innate immune system in brain com-
menced with recognition of a single marker, HLA-DR, on a single
cell type,microglia, in a single disorder,Alzheimer disease. Twenty
ﬁve years later, more than a thousand innate immune system
markers have been identiﬁed which are associated with neu-
rons, astrocytes, oligodendrocytes, and endothelial cells, as well
as microglia.
They include, but are not limited to, complement proteins
and their regulators, cytokines, chemokines, acute phase reac-
tants, prostaglandins, proteases, protease inhibitors, coagulation
factors, ﬁbrinolytic factors, anaphylatoxins, integrins, and free
radical generators. They are found in a spectrum of neuro-
logical diseases. Some stimulate inﬂammation, others inhibit it.
Shifting the balance from a mode of attack to one of healing
holds promise of having signiﬁcant therapeutic beneﬁt in a spec-
trum of degenerative diseases. Clearly there is much still to be
learned. It can be said that, despite the huge expansion of activ-
ity that has taken place in the last 25 years, it is still a ﬁeld in its
infancy.
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